SEARCH:   Advanced

Blood, 1 October 2004, Vol. 104, No. 7, pp. 2065-2072. Prepublished online as a Blood First Edition Paper on May 25, 2004; DOI 10.1182/blood-2004-02-0449. This Article Full Text (PDF) All Versions of this Article: 2004-02-0449v1 104/7/2065    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Song, J. S Articles by Colman, R. W Search for Related Content PubMed PubMed Citation Articles by Song, J. S Articles by Colman, R. W Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 5, 2004 Accepted May 4, 2004 Inhibition of Tumor Angiogenesis In Vivo by Monoclonal Antibody Targeted to Domain 5 of High Molecular Weight Kininogen James S Song, Irma M Sainz, Stephen C Cosenza, Irma Isordia-Salas, Abdel Bior, Harlan N Bradford, Yan-Lin Guo, Robin A Pixley, E P Reddy, and Robert W Colman* The Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA, USA The Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA, USA * Corresponding author; email: colmanr{at}temple.edu. We have shown that human high molecular weight kininogen is proangiogenic due to release of bradykinin. We now determined the ability of a murine monoclonal antibody to the light chain of high molecular weight kininogen, C11C1, to inhibit tumor growth compared to isotype matched murine IgG. Monoclonal antibody C11C1 efficiently blocks binding of high molecular weight kininogen to endothelial cells in a concentration-dependent manner. The antibody significantly inhibited growth of human colon carcinoma cells in a nude mouse xenograft assay and was accompanied by a significant reduction in the mean microvascular density compared to the IgG control group. We also showed that a hybridoma producing monoclonal antibody C11C1 injected intramuscularly exhibited markedly smaller tumor mass in a syngeneic host compared to a hybridoma producing a monoclonal antibody to the high molecular weight kininogen heavy chain or to an unrelated plasma protein. In addition, tumor inhibition by purified monoclonal antibody C11C1 was not due to direct anti-tumor effect since there was no decrease of tumor cell growth in vitro in contrast to the in vivo inhibition. Our results indicate that monoclonal antibody C11C1 inhibits angiogenesis and human tumor cell growth in vivo and has therapeutic potential for treatment of human cancer. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. Clapp, S. Thebault, M. C. Jeziorski, and G. Martinez De La Escalera Peptide Hormone Regulation of Angiogenesis Physiol Rev, October 1, 2009; 89(4): 1177 - 1215. [Abstract] [Full Text] [PDF] M. Bader Kallikrein-Kinin System in Neovascularization Arterioscler Thromb Vasc Biol, May 1, 2009; 29(5): 617 - 619. [Full Text] [PDF] N. Petrovic, W. Schacke, J. R. Gahagan, C. A. O'Conor, B. Winnicka, R. E. Conway, P. Mina-Osorio, and L. H. Shapiro CD13/APN regulates endothelial invasion and filopodia formation Blood, July 1, 2007; 110(1): 142 - 150. [Abstract] [Full Text] [PDF] J.-i. Yamamura, Y. Morita, Y. Takada, and H. Kawakami The Fragments of Bovine High Molecular Weight Kininogen Promote Osteoblast Proliferation In Vitro J. Biochem., December 1, 2006; 140(6): 825 - 830. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020